You might like to think about the reality that DMX-200 has a significantly better safety record than Sparsentan and has still the potential (now lacking for Sparsentan with its primary endpoint failure) to generate statistically significant reduction in the eGFR slope.
Ann: Dimerix Presents at ASX Small & Mid-Cap Conference, page-51
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $225.5M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 41.8¢ | 40.0¢ | $776.3K | 1.907M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 111946 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.0¢ | 20706 | 1 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |